Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynsey A Huxham

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
Limited tissue penetration of taxanes: a mechanism for resistance in solid tumorsAlastair H Kyle, Lynsey A Huxham, Devon M Yeoman, et al.
Cancer Research|October 3, 2003
Tumor distribution of bromodeoxyuridine-labeled cells is strongly dose dependentAlastair H Kyle, Lynsey A Huxham, Jennifer H E Baker, et al.
Cancer Research|September 3, 2004
Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell cultureAlastair H Kyle, Lynsey A Huxham, Aaron S J Chiam, et al.
Microvascular Research|March 21, 2006
Vascular-specific quantification in an in vivo Matrigel chamber angiogenesis assayJennifer H E Baker, Lynsey A Huxham, Alastair H Kyle, et al.
Microvascular Research|November 21, 2007
Exploring vascular dysfunction caused by tirapazamineLynsey A Huxham, Alastair H Kyle, Jennifer H E Baker, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 4, 2006
Tirapazamine causes vascular dysfunction in HCT-116 tumour xenograftsLynsey A Huxham, Alastair H Kyle, Jennifer H E Baker, et al.
Cancer Research|September 18, 2004
Microregional effects of gemcitabine in HCT-116 xenograftsLynsey A Huxham, Alastair H Kyle, Jennifer H E Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenograftsJennifer H E Baker, Kirstin E Lindquist, Lynsey A Huxham, et al.
Breast Cancer Research and Treatment|March 10, 2007
Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycinWieslawa H Dragowska, Maïté Verreault, Donald T T Yapp, et al.
Molecular Cancer Research : MCR|November 25, 2004
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularizationWieslawa H Dragowska, Corinna Warburton, Donald T T Yapp, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2007
Limited tissue penetration of taxanes: a mechanism for resistance in solid tumorsAlastair H Kyle, Lynsey A Huxham, Devon M Yeoman, et al.
Cancer Research|October 3, 2003
Tumor distribution of bromodeoxyuridine-labeled cells is strongly dose dependentAlastair H Kyle, Lynsey A Huxham, Jennifer H E Baker, et al.
Cancer Research|September 3, 2004
Direct assessment of drug penetration into tissue using a novel application of three-dimensional cell cultureAlastair H Kyle, Lynsey A Huxham, Aaron S J Chiam, et al.
Microvascular Research|March 21, 2006
Vascular-specific quantification in an in vivo Matrigel chamber angiogenesis assayJennifer H E Baker, Lynsey A Huxham, Alastair H Kyle, et al.
Microvascular Research|November 21, 2007
Exploring vascular dysfunction caused by tirapazamineLynsey A Huxham, Alastair H Kyle, Jennifer H E Baker, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 4, 2006
Tirapazamine causes vascular dysfunction in HCT-116 tumour xenograftsLynsey A Huxham, Alastair H Kyle, Jennifer H E Baker, et al.
Cancer Research|September 18, 2004
Microregional effects of gemcitabine in HCT-116 xenograftsLynsey A Huxham, Alastair H Kyle, Jennifer H E Baker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 3, 2008
Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenograftsJennifer H E Baker, Kirstin E Lindquist, Lynsey A Huxham, et al.
Breast Cancer Research and Treatment|March 10, 2007
Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycinWieslawa H Dragowska, Maïté Verreault, Donald T T Yapp, et al.
Molecular Cancer Research : MCR|November 25, 2004
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularizationWieslawa H Dragowska, Corinna Warburton, Donald T T Yapp, et al.
Pageof 2